Novavax, Inc. (NASDAQ:NVAX) Director James F. Young Sells 7,500 Shares of Stock

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 7,500 shares of the business’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $14.09, for a total value of $105,675.00. Following the sale, the director now owns 61,760 shares in the company, valued at approximately $870,198.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Novavax Trading Down 0.1 %

Novavax stock opened at $14.00 on Wednesday. Novavax, Inc. has a twelve month low of $3.53 and a twelve month high of $23.86. The firm’s 50 day moving average price is $11.44 and its two-hundred day moving average price is $7.06.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.01). The firm had revenue of $93.90 million for the quarter, compared to analyst estimates of $71.32 million. During the same quarter in the previous year, the business earned ($3.41) earnings per share. The company’s revenue was up 15.9% compared to the same quarter last year. As a group, sell-side analysts expect that Novavax, Inc. will post 0.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NVAX. Bank of America lifted their target price on shares of Novavax from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Friday, June 14th. JPMorgan Chase & Co. upgraded shares of Novavax from an “underweight” rating to a “neutral” rating in a research report on Friday, May 10th. TD Cowen increased their target price on Novavax from $5.00 to $10.00 and gave the company a “hold” rating in a report on Monday, May 13th. B. Riley raised their target price on Novavax from $11.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, May 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of Novavax in a research report on Monday, May 13th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Novavax currently has a consensus rating of “Hold” and a consensus target price of $19.00.

Institutional Investors Weigh In On Novavax

A number of hedge funds and other institutional investors have recently made changes to their positions in NVAX. Charles Schwab Investment Management Inc. increased its holdings in Novavax by 7.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 703,350 shares of the biopharmaceutical company’s stock worth $5,092,000 after buying an additional 51,274 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Novavax during the 3rd quarter valued at $322,000. Federated Hermes Inc. raised its holdings in shares of Novavax by 108.7% during the 3rd quarter. Federated Hermes Inc. now owns 461,827 shares of the biopharmaceutical company’s stock valued at $3,344,000 after purchasing an additional 240,514 shares in the last quarter. PEAK6 Investments LLC lifted its stake in shares of Novavax by 47.7% in the 3rd quarter. PEAK6 Investments LLC now owns 30,085 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 9,714 shares during the last quarter. Finally, Nomura Holdings Inc. bought a new stake in Novavax in the third quarter worth $74,000. 53.04% of the stock is owned by hedge funds and other institutional investors.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.